DKSH has been appointed by MSD (Thailand) Ltd. to support its expansion efforts in Thailand. This collaboration aims to enhance market coverage of MSD’s vaccines and improve accessibility to such healthcare solutions, empowering patients in the fight against HPV-related diseases.
Bangkok, Thailand, 12 December, 2024 – DKSH Business Unit Healthcare, a Strategic Healthcare Solutions Partner and leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health and medical device companies, has entered a new strategic partnership with MSD (Thailand) Ltd., the local subsidiary of a global research-intensive biopharmaceutical company. Through this collaboration, DKSH will support the commercialization of human papillomavirus (HPV) vaccines in Thailand. The partnership aims to expand market coverage and improve access to preventive healthcare for Thai patients.
This partnership marks another step forward in increasing awareness and vaccination rates for HPV in Thailand, a market that continues to face challenges in preventive care uptake.1 According to a study on “Policy and plan for vaccine production and development in Thailand: a narrative review”, the country faces challenges in ensuring adequate vaccine availability for Thai citizens, particularly during health crises and epidemics. This hampers efforts to achieve health equity and improve outcomes for vulnerable populations.
Under this agreement, DKSH will provide comprehensive Contract Sales Organization (CSO) services and patient solutions ensuring more convenient patient access to the HPV vaccine through hospitals, clinics, and health care partners throughout Thailand.
“By partnering with DKSH, we will be able to further improve healthcare consumers’ access to our vaccines, ultimately improving vaccine coverage rates,” said Dr. Mary Srethapakdi, Managing Director, MSD Thailand. “DKSH’s one hundred year presence in Thailand and their unique go-to market model gives MSD full confidence in this partnership.”
“Partnering with MSD, a globally recognized leader in medicines and vaccines, enables us to deepen our commitment to improving access and delivery of vaccines through innovative and integrated solutions to healthcare consumers,” said Patrik Grande, Vice President, Regional Head of Commercial Outsourcing APAC Healthcare, DKSH. “This collaboration brings our mission to life. With our proven expertise in developing brands with tailored go-to-market strategies, along with our extensive local network, we aim to provide greater access to MSD’s HPV vaccine.”
This partnership with MSD strengthens DKSH’s commitment to addressing critical public health needs in Thailand. As a trusted healthcare partner, DKSH ensures that innovative solutions reach the people who need them most, contributing to a healthier future for Thai communities.
1 Jumlongnark, W. (2023). Policy and plan for vaccine production and development in Thailand: narrative review. Journal of Public Health and Emergency.
(TH-GSL-00569 06/12)
About MSD (Thailand) Ltd
MSD (Thailand) Ltd., a wholly owned subsidiary of Merck & Co., Inc. With a history spanning over 70 years, starting with the supply of our first medicine to Thailand in 1949 through a trading company, MSD Thailand remains committed to being a leader in healthcare innovation and a trusted partner in maximizing patient access to our groundbreaking products. They are proud of their diverse and inclusive workforce and their responsible operations, which support a sustainable and ongoing advancement of Thailand’s public health and healthcare system. www.msd-thailand.com
About DKSH
DKSH’s purpose is to enrich people’s lives. For almost 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 29,040 specialists, generating net sales of CHF 11.1 billion in 2023. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, and over-the-counter products as well as medical devices. With around 8,140 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2023. www.dksh.com/hec